Clonal analyses of refractory testicular germ cell tumors.
Antineoplastic Agents
/ pharmacology
Biomarkers, Tumor
/ genetics
Cisplatin
/ pharmacology
Clone Cells
/ drug effects
Drug Resistance, Neoplasm
/ genetics
Genome, Human
Humans
Male
Neoplasm Metastasis
Neoplasms, Germ Cell and Embryonal
/ drug therapy
Testicular Neoplasms
/ drug therapy
Tumor Cells, Cultured
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
27
12
2018
accepted:
28
02
2019
entrez:
15
3
2019
pubmed:
15
3
2019
medline:
18
12
2019
Statut:
epublish
Résumé
Testicular germ cell tumors (TGCTs) are unique amongst solid tumors in terms of the high cure rates using chemotherapy for metastatic disease. Nevertheless, TGCTs still kill approximately 400 men per year, at a median age of 30 years, in the United States. This young age of mortality dramatically amplifies the impact of these deaths for the patients and their often young families. Furthermore the high cure rate makes it difficult to conduct further clinical trials of non curable disease. TGCTs are characterized by a marked aneuploidy and the presence of gain of chromosomal region 12p. Genomic testing may offer the ability to identify potentially lethal TGCTs at the time of initial diagnosis. However sequencing based studies have shown a paucity of somatic mutations in TGCT genomes including those that drive refractory disease. Furthermore these studies may be limited by genetic heterogeneity in primary tumors and the evolution of sub populations during disease progression. Herein we applied a systematic approach combining DNA content flow cytometry, whole genome copy number and whole exome sequence analyses to interrogate tumor heterogeneity in primary and metastatic refractory TGCTs. We identified both known and novel somatic copy number aberrations (12p, MDM2, and RHBDD1) and mutations (XRCC2, PIK3CA, RITA1) including candidate markers for platinum resistance that were present in a primary tumor of mixed histology and that remained after tandem autologous stem cell transplant.
Identifiants
pubmed: 30870501
doi: 10.1371/journal.pone.0213815
pii: PONE-D-18-36907
pmc: PMC6417677
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers, Tumor
0
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0213815Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Hum Pathol. 2017 Jan;59:10-25
pubmed: 27569298
Lab Invest. 1989 Jan;60(1):14-21
pubmed: 2536126
Nat Genet. 2010 Jul;42(7):604-7
pubmed: 20543847
Genome Med. 2014 Jan 31;6(1):9
pubmed: 24484537
Hum Mutat. 2013 Jan;34(1):255-65
pubmed: 22949387
Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):12054-9
pubmed: 21730190
Lancet. 2006 Mar 4;367(9512):754-65
pubmed: 16517276
Nat Genet. 2014 Feb;46(2):107-115
pubmed: 24362816
Drugs. 2006;66(5):641-59
pubmed: 16620142
Nat Rev Urol. 2016 Jul;13(7):409-19
pubmed: 27296647
Cell Rep. 2018 Jun 12;23(11):3392-3406
pubmed: 29898407
Neoplasia. 2015 Feb;17(2):167-74
pubmed: 25748235
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947
pubmed: 30371878
Am J Cancer Res. 2012;2(2):153-67
pubmed: 22432056
Cancer Res. 2005 Sep 15;65(18):8085-9
pubmed: 16166280
PLoS One. 2012;7(11):e50586
pubmed: 23226320
Nature. 2016 Nov 30;540(7631):114-118
pubmed: 27905446
Oncogene. 2003 Jun 19;22(25):3859-66
pubmed: 12813459
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
pubmed: 11752295
Cell. 2012 May 25;149(5):979-93
pubmed: 22608084
J Clin Oncol. 2016 Nov 20;34(33):4000-4007
pubmed: 27646943
Eur Urol. 2015 Jul;68(1):77-83
pubmed: 25597018
J Natl Cancer Inst. 2008 Dec 17;100(24):1763-70
pubmed: 19066273
Target Oncol. 2016 Jun;11(3):363-70
pubmed: 26661077
Sci Transl Med. 2012 Mar 28;4(127):127ps10
pubmed: 22461637
Cell Mol Life Sci. 2008 Nov;65(23):3822-9
pubmed: 18953687
Cell Mol Life Sci. 2019 May;76(9):1713-1727
pubmed: 30671589
BMC Genomics. 2014 Jul 09;15:579
pubmed: 25011954
Biochem Biophys Res Commun. 2007 Jan 19;352(3):763-8
pubmed: 17141189
BMC Cell Biol. 2009 Apr 10;10:25
pubmed: 19358743
Cell. 2012 May 25;149(5):994-1007
pubmed: 22608083
Crit Rev Oncol Hematol. 2014 Mar;89(3):366-85
pubmed: 24182421
Nature. 2010 Oct 28;467(7319):1114-7
pubmed: 20981102
Int J Androl. 2011 Aug;34(4 Pt 2):e266-73
pubmed: 21790652
J Comput Biol. 2006 Mar;13(2):215-28
pubmed: 16597236
Br J Cancer. 2017 Aug 8;117(4):572-582
pubmed: 28720843
Nat Commun. 2015 Jan 22;6:5973
pubmed: 25609015
Breast Cancer Res. 2018 Jul 11;20(1):71
pubmed: 29996881